Breaking News

Catalent, Ethicann Partner on Fast-Dissolve Treatment

Will leverage Catalent’s Zydis ODT technology to develop a new pharmaceutical-grade CBD and THC product to treat spasticity in MS patients

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent has entered into a partnership with Ethicann Pharmaceuticals Inc., a pharmaceutical company using cannabinoid oils to formulate prescription drugs. The program will initially focus on using Catalent’s Zydis orally disintegrating tablet technology to develop a new combination pharmaceutical-grade cannabidiol (CBD) and tetrahydrocannabinol (THC) product that, if approved, would trat patients suffering from multiple sclerosis (MS) spasticity. Ethicann will investigate the new Zydis prod...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters